Does reduced kidney function limit conversion of 25(OH)D to active 1,25(OH)2D?

In patients with declining kidney function, the metabolic activation of vitamin D is significantly impaired through both structural and hormonal mechanisms, leading to systemic signaling deficiencies.

Clinical evidence of impaired metabolism

Research demonstrates that the kidney's ability to convert 25-hydroxyvitamin D (25(OH)D) into the active 1,25-dihydroxyvitamin D (1,25(OH)₂D or calcitriol) begins to decline relatively early in the progression of chronic kidney disease (CKD).

• Threshold for decline: Clinical studies show that 1,25(OH)₂D levels begin to fall significantly when the estimated glomerular filtration rate (eGFR) drops below 60 mL/min/1.73 m², with a steep and consistent decline once eGFR falls below 45–50 mL/min/1.73 m².
• Enzymatic limitation: The primary enzyme responsible for this conversion, CYP27B1 (1-alpha-hydroxylase), is located in the proximal tubular cells. As renal mass is lost, the "factory" for active vitamin D production physically diminishes.
• Substrate-product ratio: In advanced CKD, patients exhibit an inappropriately low 1,25(OH)₂D to 25(OH)D ratio, indicating that even when the precursor is available, the conversion process is bottlenecked.

Mechanistic explanations

The reduction in vitamin D signaling is not merely a consequence of passive tissue loss but is actively modulated by endocrine feedback loops.

• FGF23 suppression: As kidney function declines, the body increases production of Fibroblast Growth Factor 23 (FGF23) to manage phosphate levels. High FGF23 levels directly suppress the transcription of the CYP27B1 enzyme while simultaneously upregulating CYP24A1, the enzyme responsible for degrading existing active vitamin D.
• Vitamin D resistance: In later stages of kidney disease, target tissues (such as the parathyroid glands and bone) exhibit true "resistance." This is characterized by a downregulation of Vitamin D Receptors (VDR) and impaired receptor activation, meaning that even if calcitriol is provided, the cellular response is blunted.

Clinical implications for signaling

The failure of these signaling pathways has broad systemic effects beyond bone health.

• Mineral homeostasis: Reduced signaling in the gut impairs intestinal calcium absorption by downregulating VDR-dependent transport proteins like TRPV6 and calbindin-D9k.
• Secondary hyperparathyroidism: The loss of VDR signaling in the parathyroid gland prevents the normal suppression of parathyroid hormone (PTH) synthesis, leading to the development of secondary hyperparathyroidism.
• Tissue protection: Reduced VDR activation in renal podocytes and tubules contributes to inflammation and fibrogenesis, potentially accelerating the progression of kidney disease.

Bottom line

Reduced kidney function limits the conversion of 25(OH)D to active 1,25(OH)₂D through the physical loss of proximal tubular cells and the hormonal suppression of CYP27B1 by FGF23. This deficiency, combined with receptor-level resistance, significantly impairs vitamin D signaling, leading to disrupted mineral metabolism and the loss of protective anti-inflammatory pathways.